Impact of autologous hematopoietic cell transplant (HCT) followed by dendritic cell/myeloma fusion vaccine with lenalidomide maintenance in increasing multiple myeloma (MM) immunity (BMT CTN 1401) Meeting Abstract


Authors: Chung, D. J.; Shah, N.; Stroopinsky, D.; Wu, J.; Bisharat, L.; Callander, N. S.; Logan, B. R.; Anderson, K. C.; Chodon, T.; Mohan, M.; Devine, S.; Efebera, Y. A.; Geller, N.; Hematti, P.; Holmberg, L. A.; Howard, A.; Johnson, B.; Lazarus, H. M.; Malek, E.; McCarthy, P. L.; McKenna, D. H.; Mendizabal, A. M.; Munshi, N. C.; O'Donnell, L.; Rapoport, A. P.; Nooka, A. K.; Reese, J.; Soiffer, R. J.; Uhl, L.; Cheloni, G.; Karagkouni, D.; Vlachos, I.; Young, J. W.; Rosenblatt, J.; Waller, E. K.; Pasquini, M. C.; Avigan, D.
Abstract Title: Impact of autologous hematopoietic cell transplant (HCT) followed by dendritic cell/myeloma fusion vaccine with lenalidomide maintenance in increasing multiple myeloma (MM) immunity (BMT CTN 1401)
Meeting Title: 63nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 138
Issue: Suppl. 1
Meeting Dates: 2021 Dec 11-14
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2021-11-23
Language: English
ACCESSION: WOS:000736398803196
DOI: 10.1182/blood-2021-149659
PROVIDER: wos
Notes: Meeting Abstract: 899 -- Hybrid meeting, also took place online -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Chung
    240 Chung
Related MSK Work